Adjuvant-mediated enhancement of the immune response to HIV vaccines

Sneha Ratnapriya, Eva Perez-Greene, Luca Schifanella, Alon Herschhorn

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations


Protection from human immunodeficiency virus (HIV) acquisition will likely require an effective vaccine that elicits antibodies against the HIV-1 envelope glycoproteins (Envs), which are the sole target of neutralizing antibodies and a main focus of vaccine development. Adjuvants have been widely used to augment the magnitude and longevity of the adaptive immune responses to immunizations with HIV-1 Envs and to guide the development of specific immune responses. Here, we review the adjuvants that have been used in combination with HIV-1 Envs in several preclinical and human clinical trials in recent years. We summarize the interactions between the HIV-1 Envs and adjuvants, and highlight the routes of vaccine administration for various formulations. We then discuss the use of combinations of different adjuvants, the potential effect of adjuvants on the elicitation of antibodies enriched in somatic hypermutation and containing long complementarity-determining region 3 of the antibody heavy chain, and the elicitation of non-neutralizing antibodies.

Original languageEnglish (US)
JournalFEBS Journal
StatePublished - 2021

Bibliographical note

Funding Information:
This work was supported by Center Grant of the Academic Investment Research Program (AIRP) of the Medical School at the University of Minnesota.

Publisher Copyright:
© 2021 Federation of European Biochemical Societies


  • adjuvants
  • envelope glycoproteins
  • HIV-1
  • immune response
  • vaccines

PubMed: MeSH publication types

  • Journal Article
  • Review
  • Research Support, Non-U.S. Gov't


Dive into the research topics of 'Adjuvant-mediated enhancement of the immune response to HIV vaccines'. Together they form a unique fingerprint.

Cite this